Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics

Figure 5

APOE-related changes in LDL-cholesterol levels in patients with dementia treated with E-SAR-94010. Tb: basal LDL-cholesterol (LDL-CHO) levels prior to treatment; Tt: LDL-CHO levels after 3 months of treatment in the total sample. E2/3b: basal LDL-CHO levels in APOE-2/3 carriers; E2/3t: LDL-CHO levels after treatment in APOE-2/3 carriers; E2/4b: basal LDL-CHO levels in APOE-2/4 carriers; E2/4t: LDL-CHO levels after treatment in APOE-2/4 carriers; E3/3b: basal LDL-CHO levels in APOE-3/3 carriers; E3/3t: LDL-CHO levels after treatment in APOE-3/3 carriers; E3/4b: basal LDL-CHO levels in APOE-3/4 carriers; E3/4t: LDL-CHO levels after treatment in APOE-3/4 carriers; E4/4b: basal LDL-CHO levels in APOE-4/4 carriers; E4/4: LDL-CHO levels after treatment in APOE-4/4 carriers.